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n Evidence summary
Three large cohort studies determined 
that African Americans have a higher 
prevalence of hypertension and worse 
cardiovascular and renal outcomes 
when compared with white Americans. 
For African American patients, the stan-
dard blood pressure goals apply: below 
c l i n i c a l  c o m m e n t a r y
African Americans respond better to 
combination ACE inhibitor plus diuretic
Treat	 african	 american	 patients	 with	 hy-
pertension	according	to	the	Joint	National	
Committee	 on	Prevention,	Detection,	 and	
Treatment	 of	 High	 blood	 Pressure	 (JNC	
7)	 guidelines.	 These	 guidelines	 state	 that	
patients	with	stage	1	hypertension,	regard-
less	of	race,	should	be	treated	with	lifestyle	
modification	(to	include	a	low-salt	diet	and	
weight	loss)	for	3	months.	If,	after	a	trial	of	
lifestyle	 modification,	 these	 patients	 still	
have	hypertension,	then	start	diuretic	thera-
py	while	continuing	lifestyle	modifications.	
			If	patients	present	with	stage-2	hypertension,	
started	them	on	a	diuretic	plus	another	agent.	
african	american	patients	do	not	respond	to	
aCe	 inhibitor	monotherapy	well,	 but	do	 re-
spond	to	the	combination	of	an	aCe	inhibitor	
plus	diuretic.	 If	 patients,	 regardless	of	 race,	
have	 comorbid	 conditions	 that	 lend	 them-
selves	to	alternate	antihypertensive	treatment	
(ie,	beta-blocker	therapy	post–myocardial	in-
farction),	then	use	these	therapies	first-line.
Mandi Sehgal, MD
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e v i d e n c e - b a s e d  a n s w e r
In	 african	 americans	 with	 hypertension,	
therapy	 is	 best	 initiated	 with	 the	 low-	
sodium	 Dietary	 approaches	 to	 stop	 Hy-
pertension	 (DasH)	 diet	 and	 a	 thiazide-
type	diuretic	(strength	of	recommendation	
[sor]:	A,	based	on	randomized	controlled	
trials).	 If	 the	 blood	 pressure	 goal	 is	 not	
achieved	 with	 thiazide	 monotherapy,	 a	
calcium	 channel	 blocker,	 angiotensin-	
converting	 enzyme	 (aCe)	 inhibitor,	
angiotensin	II	receptor	blocker	(arb),	or	a	
beta-blocker	 can	 be	 added.	 an	 initial	
combination	 treatment	 is	 recommended	
for	 patients	 with	 systolic	 blood	 pressure	
>15	 mm	 Hg	 or	 diastolic	 blood	 pressure	
>10	mm	Hg	above	target	(sor:	C,	expert	
opinion).	
	 	 	african	americans	have	reduced	blood	
pressure	 responses	 to	monotherapy	with	
beta-blocker,	aCe	inhibitor,	or	arbs	when	
compared	to	diuretics	or	calcium	channel	
blockers	 (sor:	A,	 randomized	 controlled	
trials).	However,	cardiac	and	renal	 indica-
tions	 for	 prescribing	 these	 medications	
should	be	equally	applied	to	african	amer-
ican	patients	(sor:	C,	expert	opinion).
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140/90 mm Hg with uncomplicated 
hypertension and below 130/80 with 
diabetes or renal disease.1
Dietary interventions
An RCT compared the effects of con-
suming the DASH diet (consisting of 
4–5 servings of fruit, 4–5 servings of 
vegetables, 2–3 servings of low-fat dairy 
per day, and <25% fat) with a typical 
high-fat control diet among 459 adults 
with normal or elevated blood pressure.2 
Among 133 patients with hypertension, 
the DASH diet reduced systolic and dia-
stolic blood pressure by 11.4 mm Hg 
(97.5% confidence interval [CI], –15.9 
to –6.9) and 5.5 mm Hg (97.5% CI, 
–8.2 to –2.7) respectively when com-
pared with the control diet. Among 
African Americans with hypertension, 
the DASH diet was even more benefi-
cial, reducing their systolic and diastolic 
blood pressure by 13.2 mm Hg and 6.1 
mm Hg respectively.1 
Another RCT studied the effect 
of different levels of dietary sodium 
in conjunction with the DASH diet.3 
A total of 412 participants were ran-
domly assigned to eat either a control 
diet or the DASH diet. Within the 
assigned diet, participants ate foods 
with high (150 mmol/d), intermediate 
(100 mmol/d), and low (50 mmol/d) 
levels of sodium in random order. In 
this study, low-sodium DASH diet 
was associated with additional lower-
ing of blood pressure, an effect that 
was also found to be stronger for 
African Americans patients than oth-
ers.3 When compared with the combi-
nation of the control diet and a high 
level of sodium, the DASH diet and 
a low level of sodium lowered sys-
tolic blood pressure by 11.5 mm Hg 
for participants with hypertension 
(12.6 mm Hg for blacks; 9.5 mm Hg 
for others), and by 7.1 mm Hg for 
participants without hypertension 
(7.2 mm Hg for blacks; 6.9 mm Hg 
for others).3 
Medical interventions
The Antihypertensive and Lipid-Lower-
ing Treatment to Prevent Heart Attack 
Trial4 (ALLHAT) and African Ameri-
can Study of Kidney Disease and Hy-
pertension5 (AASK) have demonstrated 
the benefit of blood pressure reduction 
using specific classes of antihypertensive 
agents. 
The ALLHAT trial, a double-blind 
RCT of 42,448 high-risk hypertensive pa-
tients aged >55 years, compared chlortha-
lidone (a thiazide-type diuretic) with am-
lodipine (Norvasc), lisinopril (Prinivil, 
Zestril), or doxazosin (Cardura). In this 
study, which included 36% African Amer-
icans, chlorthalidone, lisinopril, and amlo-
dipine did not differ in preventing major 
cardiovascular events. However, lisinopril 
was associated with an increased risk for 
heart failure (relative risk [RR] for African 
Americans=1.32; 95% CI, 1.11–1.58) and 
stroke (RR for African Americans=1.4; 
95% CI, 1.17–1.68), and amlodipine 
was associated with a higher risk of heart 
failure (RR in African Americans=1.47; 
95% CI, 1.24–1.74). Additionally, ACE 
inhibitor–induced angioedema or cough 
occurred more frequently among African 
American patients than white patients.4 
Although a randomized controlled 
trial5 and a review of multiple studies6 
demonstrated that African Americans 
may be less responsive to monotherapy 
with ACE inhibitors, the AASK trial con-
firmed that ACE inhibitors can provide 
significant clinical benefits for African 
Americans with hypertensive renal dis-
ease. AASK, a double-blind RCT of 1094 
African American patients with renal 
insufficiency, compared the effects of an 
ACE inhibitor (ramipril [Altace]), a di-
hydropyridine calcium channel blocker 
(amlodipine), or a beta blocker (meto-
prolol [Lopressor]) on the progression of 
hypertensive renal disease. 
The study showed a 44% relative risk 
reduction (95% CI, 13%–65%; num-
ber needed to treat [NNT]=25) in pro-
gression to end-stage renal disease, and 
a significant decrease in the combined 
Start therapy  
with a low-sodium 
DASH diet  
and a thiazide 
diuretic
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endpoints of glomerular filtration rate 
events (decrease >50%), end-stage renal 
disease, and death (decreased by 38%) 
in the ramipril group compared with the 
amlodipine group (95% CI, 13%–56%; 
NNT=56 per patient-year).5,7 Metopro-
lol appeared to have intermediate out-
comes.8
Recommendations from others
Both the International Society on Hy-
pertension in Blacks (ISHIB) guidelines1 
and the JNC 79 recommend therapeu-
tic lifestyle modification that includes 
DASH diet, dietary sodium restriction, 
and weight reduction. Both guidelines 
recognize the importance of thiazide di-
uretics and recommend its use as first-
line therapy or as a part of combination 
therapy for hypertension among African 
Americans. They also recommend ini-
tiating therapy with 2 agents for blood 
pressure significantly above target level 
(20/10 mm Hg above target per JNC 7, 
15/10 mm Hg above target per ISHIB). 
The ISHIB report emphasizes the need 
for not overlooking renal protection with 
an ACE inhibitor for African Americans 
with renal disease. The American Diabetes 
Association recommends that all patients 
with diabetes and hypertension be treated 
with a regimen that includes either an ACE 
inhibitor or an ARB.10 n
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